WO2020040621A1 - Composition visant à favoriser la différenciation ou la prolifération de cellules souches adipeuses humaines - Google Patents

Composition visant à favoriser la différenciation ou la prolifération de cellules souches adipeuses humaines Download PDF

Info

Publication number
WO2020040621A1
WO2020040621A1 PCT/KR2019/010815 KR2019010815W WO2020040621A1 WO 2020040621 A1 WO2020040621 A1 WO 2020040621A1 KR 2019010815 W KR2019010815 W KR 2019010815W WO 2020040621 A1 WO2020040621 A1 WO 2020040621A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
extract
sodium
composition
xanthophyll
Prior art date
Application number
PCT/KR2019/010815
Other languages
English (en)
Korean (ko)
Inventor
이선주
김미나
김미선
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180109108A external-priority patent/KR102311011B1/ko
Priority claimed from KR1020190029998A external-priority patent/KR102199678B1/ko
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Priority to JP2021534101A priority Critical patent/JP2021535208A/ja
Priority to CN201980055771.1A priority patent/CN112638357B/zh
Priority to US17/270,697 priority patent/US20210315799A1/en
Priority to CN202410183350.XA priority patent/CN118021632A/zh
Publication of WO2020040621A1 publication Critical patent/WO2020040621A1/fr
Priority to JP2023174389A priority patent/JP2024009897A/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention is formononetin (Formononetin), Emodin (Emodin), Artepillin (Artepillin C), Carnosic acid (Carnosic acid), Palmitamide (Palmitamide), Sodium Guaiazulene Sulfonate (Sodium Guaiazulene Sulfonate), Caffeic Acid, Acetyl Mandelic Acid, Laccaic Acid, Ubiquinone, Hydroxycinnamic Acid, Xanthophyll, Raspberry ketone, Gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate ), Menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, pak extract, aloe extract, fractions of the extract Cosmetic composition for increasing skin elasticity and improving wrinkles, food composition, pharmaceutical composition,
  • Adipose tissue plays a role in supporting the skin structure along with the muscles, and it is an important cell structurally so that the number of fat cells is 30-40% in number but 90% in volume.
  • Subcutaneous adipose tissue decreases with aging of the individual, and accordingly, it is known that the elasticity of the skin decreases and wrinkles are generated a lot.
  • the elasticity of the facial part decreases and wrinkles can be seen a lot. Therefore, increasing the volume in the skin by controlling the number of fat tissues that play an important role in maintaining the structure in the skin may be an improvement of skin elasticity and wrinkles.
  • the transplanted stem cells have a very low in vivo engraftment rate, and need to be reoperated after a certain time and the transplanted fats aggregate. Therefore, it is essential to study the material that can strengthen the structure of the subcutaneous fat layer without such surgery.
  • the lips in the skin are not only the most moving parts of the body by repeating the constant contraction and expansion, but also always exposed to the extreme environment is easily affected by environmental factors such as ultraviolet, cold, dry.
  • the lips have a different structure than normal skin, and their own defense ability is weak, and as they age, the volume decreases and wrinkles increase, thereby losing an attractive shape.
  • the currently developed technology is a technology that uses wrinkle improvement ingredients studied for facial skin as it is, and a temporary volume. There are only techniques that give an increase. The latter increase in volume is limited to stimulus responses (Korean Publication 10-2012-0140450 A).
  • Adipokine secreted by adipose-derived stem cells, is known to not only increase collagen synthesis in the dermal layer but also affect skin regeneration.
  • a result of targeting adipose progenitor cells of a mouse is low in efficiency when applied to human adipose derived stem cells.
  • the inventors of the present invention sought to find a substance that effectively promotes the differentiation of adipocyte-derived stem cells into adipocytes or the proliferation of adipocyte-derived stem cells, and as a result, substances capable of promoting the process of human adipose derived stem cells into adipocytes.
  • One object of the present invention is formononetin, (Emodin), Artemipillin (Artepillin C), Carnosic acid (Palmitamide), Sodium Guazulene sulfonate (Sodium) Guaiazulene Sulfonate, Caffeic Acid, Acetyl Mandelic Acid, Laccaic Acid, Ubiquinone, Hydroxycinnamic Acid, Xanthophyll, Raspberry Ketone Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate (sodium riboflavin phosphate), menadione, menadione, thioctic acid, lactoflavin, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, peppermint extract, aloe extract, the extract It is to provide a cosmetic composition
  • Another object of the present invention is to formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, It is to provide a food composition for increasing skin elasticity and improving wrinkles, which comprises at least one substance selected from the group consisting of xanthophyll, pak bak extract, aloe extract, fraction of pak pak extract and fraction of aloe extract.
  • Another object of the present invention is to formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, Xanthophyll, Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, pepper extract,
  • a pharmaceutical composition for increasing skin elasticity and improving wrinkles comprising aloe extract, at least one substance selected from the group consisting of fractions of the extract as an active ingredient It is to give.
  • Another object of the present invention is to formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, Xanthophyll, Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, pepper extract, Aloe extract, quasi-drug composition for increasing skin elasticity and improving wrinkles comprising at least one substance selected from the group consisting of fractions of the extract as an active ingredient To provide.
  • Another object of the present invention is for formonenetine, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid , Xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol (lanosterol), sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, pepper extract , Aloe extract, composition for promoting differentiation of human adipose derived stem cells comprising at least one substance selected from the group consisting of fractions of the extract as an active ingredient To provide.
  • Yet another object of the present invention is to provide a method for increasing skin elasticity, comprising administering the composition to a subject other than a human.
  • composition of the present invention promotes the differentiation of human adipose derived stem cells into adipocytes, or promotes the proliferation of human adipose derived stem cells to strengthen the subcutaneous fat layer structure, increase skin elasticity and improve wrinkles for anti-aging purposes. Can be used.
  • Figure 1 shows the result of staining lipids in adipocytes differentiated with oil red o after treatment with formononetin, acetyl mandelic acid and hubac extract to human adipose derived stem cells.
  • FIG. 2 shows formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, thick extract And it shows quantitatively the relative differentiation rate of human adipose derived stem cells treated with aloe extract.
  • Figure 3 shows the results of comparing the number of people around the eyes and lip wrinkles of the bakbak extract.
  • Figure 4a shows the persistence of lip wrinkle improvement until the 12th week of the subject 1 when the bakbak extract treatment
  • Figure 4b shows the persistence of lip wrinkle improvement until the week 12 of the subject 2.
  • Figure 5 shows the results of comparing the improvement of the eye area and lip wrinkles of the bakbak extract and the conventional wrinkle improvement material Asiaticoside.
  • Figure 6 shows raspberry ketones, gallic acid, caffeic acid, carnosic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin, xanthophyll, Onion, rice bran, bamboo, carrot, and hibiscus extracts were treated with human adipose derived stem cells.
  • One embodiment of the present invention is formononetin, (Emodin), Artepillin (Artepillin C), Carnosic acid (Palmitamide), Sodium Guazulene sulfonate (Sodium) Guaiazulene Sulfonate, Caffeic Acid, Acetyl Mandelic Acid, Laccaic Acid, Ubiquinone, Hydroxycinnamic Acid, Xanthophyll, Raspberry Ketone Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate (sodium riboflavin phosphate), menadione, menadione, thioctic acid, lactoflavin, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, peppermint extract, aloe extract, the extract Provided is a cosmetic composition for increasing
  • another embodiment of the present invention is the formmononetine, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxy Cosmetically acceptable salts of succinic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin or xanthophyll It provides a cosmetic composition for increasing skin elasticity and wrinkles, comprising as an active ingredient.
  • “cosmetically acceptable salts” include formononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone , Hydroxycinnamic acid raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin or xanthophyll combined with other substances
  • a salt it means a substance which can cosmetically exhibit a similar activity as the compound, but is not limited thereto.
  • the inventors of the present invention intensively tried to develop a substance capable of activating and restoring the aged subcutaneous fat layer, and as a result, formononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, cafe Acids, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone (tropolone), glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract , Rice Bran Extract, Bamboo Extract, Carrot Extract, Hibiscus Extract, Thick Extract and Aloe Extract promote the differentiation of human fat-derived stem cells into adipocytes A substance that can stimulate the growth of fat-derived stem cells were
  • composition comprising the material can be used as a cosmetic composition for increasing skin elasticity and wrinkles.
  • the skin elasticity and wrinkle improvement effect of the material is not known at all until now, it is very significant in that it was first developed by the present inventors.
  • the formmononetine of the present invention can be isolated from plants including licorice, it is not limited to its obtaining method, and chemically synthesized by methods known in the art or commercially available materials can be used.
  • the molecular formula of the term "Emodin” of the present invention is C 15 H 10 O 5 ,
  • the molecular weight is 270.24, which can be represented by the following formula (2).
  • Emodine of the present invention is not limited to the method for obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the molecular formula of the term "Artepillin C" of the present invention is C 19 H 24 O 3, the molecular weight is 300.40, it can be represented by the formula (3) below.
  • Artephylline C of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • Carnosic acid of the present invention is C 20 H 28 O 4 , the molecular weight is 332.44, it may be represented by the formula (4).
  • the carnoic acid of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • palmitamide of the present invention is a normal chain fatty acid amide having 16 carbon atoms, a molecular formula of C 16 H 33 NO, a molecular weight of 255, and may be represented by the following Chemical Formula 5.
  • Palmitamide of the present invention is not limited to its acquisition method, and chemically synthesized by methods known in the art, or commercially available materials may be used.
  • the molecular formula of the term "Sodium Guaiazulene Sulfonate" of the present invention is C 15 H 17 NaO 3 S, the molecular weight is 300.35, it can be represented by the formula (6).
  • the sodium guazulene sulfonate of the present invention is not limited to its acquisition method, and chemically synthesized by a method known in the art, or a commercially available material can be used.
  • the molecular formula of the term "Caffeic Acid” of the present invention is C 9 H 8 O 4 , the molecular weight is 180.157, it can be represented by the formula (7).
  • the caffeic acid of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • Acetyl Mandelic Acid of the present invention may be specifically "O-acetyl mandelic acid", the molecular formula is C 10 H 10 O 4 , molecular weight is 194.186, It may be represented by the formula (8) below.
  • Acetyl mandelic acid of the present invention is not limited to its acquisition method, and may be chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the term "Laccaic Acid” of the present invention is one of natural anthraquinones and is a dark red crystal produced by condensing secretions of Laccifer lacca Kerr , and is known to be mainly used as a dye.
  • the lacaic acid is not particularly limited thereto, but may be lacaic acid A, B, C, D, E or F.
  • 50506 Natural red 25 manufactured by Sigma-Aldrich was used as the laccaic acid.
  • Lacaic acid of the present invention is not limited to the method for obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • Ubiquinone of the present invention is one of fat-soluble quinones and is a constituent of the electron transport system of mitochondria.
  • the ubiquinone may be ubiquinone (10), but is not limited thereto.
  • the molecular formula is C 59 H 90 O 4
  • the molecular weight is 863.37, and may be represented by Formula 9 below.
  • the ubiquinone of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material can be used.
  • Hydroxycinnamic Acid of the present invention is C 9 H 8 O 3 , the molecular weight is 164.158, the isomer according to the position of the -OH group directly substituted in the benzene ring (o-, m-, p-hydroxycinnamic acid) and double isomers (cis-type coumarinic acid and trans-type coumaric acid) may be included, and specifically, may be m-Coumaric acid, It is not particularly limited thereto.
  • the hydroxycinnamic acid may be represented by the following Formula 10.
  • the hydroxycinnamic acid of the present invention is not limited to its acquisition method, and chemically synthesized by a method known in the art, or a commercially available material can be used.
  • Xanthophyll of the present invention is a carotenoid-based oxycarotenoid pigment present in green parts of leaves, flowers, fruits, etc. of plants, and yellow color, and the molecular formula is C 40 H 56 O 2 , molecular weight is 569. .
  • the xanthophyll may be specifically lutein, and may be represented by Formula 11 below.
  • Xanthophyll or lutein of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the molecular formula of the term “Raspberry ketone” of the present invention is C 10 H 12 O 2 , the molecular weight is 164.20, and may be represented by the following Chemical Formula 12.
  • the raspberry ketone of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the molecular formula of the term “gallic acid” of the present invention is C 7 H 6 O 5 , the molecular weight is 170.12, and may be represented by the following Chemical Formula 13.
  • the gallic acid of the present invention is not limited to the obtaining method thereof, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the molecular formula of the term “terpineol” of the present invention is C 10 H 18 O, the molecular weight is 154, it may be represented by the formula (14).
  • Terpineol of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • sodium mannose phosphate in the present invention is C 6 H 12 O 9 PNA, molecular weight is 282.12.
  • the sodium mannose phosphate may be sodium mannose 6-phosphate, or D-mannose-6-phosphate sodium salt (D-Mannose-6-phosphate sodium salt), but is not limited thereto. Can be.
  • the sodium mannose phosphate of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material can be used.
  • the molecular formula of the term "tropolone" of the present invention is C 7 H 6 O 2 , the molecular weight is 122, it may be represented by the formula (16) below.
  • the tropolone of the present invention is not limited to its acquisition method, and chemically synthesized by a method known in the art, or a commercially available material can be used.
  • the molecular formula of the term “glycyrrhetinic acid” of the present invention is C 30 H 46 O 4 , a molecular weight of 471, and may be represented by the following Chemical Formula 17.
  • the glycyrrhetinic acid of the present invention is not limited to its acquisition method, and chemically synthesized by a method known in the art, or a commercially available material can be used.
  • the molecular formula of the term "lanosterol” of the present invention is C 30 H 50 O, the molecular weight is 427, it can be represented by the formula (18).
  • the lanosterol of the present invention is not limited to the obtaining method thereof, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the molecular formula of the term "sodium riboflavin phosphate" of the present invention is C 17 H 20 N 4 NaO 9 P, the molecular weight is 478.33, it can be represented by the formula (19).
  • the sodium riboflavin phosphate of the present invention is not limited to its acquisition method, and may be chemically synthesized by a method known in the art, or a commercially available material may be used.
  • menadione of the present invention is a yellow crystal which is a kind of vitamin K.
  • the molecular formula is C 11 H 8 O 2 , the molecular weight is 172.18, and may be represented by the following Chemical Formula 20.
  • Menadione of the present invention is not limited to the method for obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • thioctic acid of the present invention is also referred to as lipoic acid (lipoic acid), the molecular formula is C 8 H 14 O 2 S 2 , the molecular weight is 206, it can be represented by the formula 21 below.
  • the thioxane or lipoic acid of the present invention is not limited to its acquisition method, and chemically synthesized by methods known in the art, or commercially available materials can be used.
  • lactoflavin refers to riboflavin (vita B 2 ) isolated from milk.
  • lactoflavin is C 17 H 20 N 4 O 6 , the molecular weight is 376.36, it can be represented by the following formula (22).
  • the lactoflavin of the present invention is not limited to the method of obtaining the same, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the compounds may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.
  • onion ( Allium cepa )” of the present invention is a biennial herb of a monocotyledonous genus Liliaceae, which is known as an anti-inflammatory, glycemic control, lowering blood pressure, including quercetin, chromium and allicin as main components. .
  • the onion may be purchased commercially, or may be used without limitation what is collected or grown in nature, and may be used without limitation, roots, stems, leaves and the like.
  • rice bran refers to a pulverized mixture such as skin, seed, and whistle layer, which is produced when milled brown rice to make white rice, and minerals such as vitamin B1, B2, niacin, and oranol, tocopherol and phytic acid. Including blood lowering cholesterol, antioxidants, anticancer and other actions are known.
  • bamboo (bamboo, Bambusoideae ) of the present invention is an evergreen perennial plant belonging to a monocotyledonous plant rice plant and bamboo subfamily, and is known for its antioxidant, bactericidal and anticancer effects.
  • the bamboo can be purchased commercially, or can be used without limitation that is collected or cultivated in nature, can be used without limitation, roots, stems, leaves and the like.
  • carrot (carrot, Daucus carota var. Known.
  • the carrots can be purchased commercially, can be used without limitation to those collected or grown in nature, roots, stems, leaves and the like can be used without limitation.
  • Rose of China refers to a plant belonging to the genus Maltew Mallow and Mugunghwa, and is rich in hibiscus acid, hydroxycitric acid, and the like, and is known as an effect of preventing obesity.
  • the hibiscus can be purchased commercially, or can be used without limitation that is collected or cultivated in nature, roots, stems, leaves and the like can be used without limitation.
  • magnolia (Magnoliae Cortex)
  • lignans and the essential oil to be dried stems and root bark of the magnolia magnolia plants, the main active ingredient.
  • Takbak is known to have effects such as anti-inflammatory, analgesic, smooth muscle control and anti-ulcer.
  • the grommets can be purchased commercially, or can be used without limitation to those collected or grown in nature.
  • Aloe vera of the present invention is a perennial plant belonging to the genus Lilies and Aloe, also called presbyopia. Its main active ingredients include aloe, aloe emodine, aloetin, alomitine, etc., and are known to act as antibacterial, antifungal and antitumor.
  • the aloe may be purchased commercially, or may be used without limitation, collected or grown in nature.
  • extract of the present invention is a liquid component obtained by immersing a desired material in various solvents, and then extracting for a predetermined time at room temperature, low temperature or warm state, obtained by removing the solvent from the liquid component It means the result of solid content.
  • it can be comprehensively interpreted to include all of the dilution of the resultant, their concentrates, their modifiers, purified products and the like.
  • the extract may be onion, rice bran, bamboo, carrot, hibiscus, bakbak or aloe extract.
  • the extract can be extracted from various organs of natural, hybrid, variegated plants, and can be extracted from plant tissues as well as roots, grounds, stems, leaves, flowers, trunks of fruits, bark of berries.
  • the extract can be obtained by extraction with water or various organic solvents.
  • the organic solvent to be used is not particularly limited as long as the extract can be obtained, but specifically, may be water, a polar solvent or a non-polar solvent, more specifically water, a lower alcohol having 1 to 6 carbon atoms ( Methanol, ethanol, propanol or butanol, etc.), polyhydric alcohols such as glycerin and butylene glycol, hydrocarbon solvents such as methyl acetate and ethyl acetate or mixed solvents thereof, or more specifically water, lower alcohols, 1,3- Butylene glycol, or a mixed solvent thereof.
  • a polar solvent or a non-polar solvent more specifically water, a lower alcohol having 1 to 6 carbon atoms ( Methanol, ethanol, propanol or butanol, etc.)
  • polyhydric alcohols such as glycerin and butylene glycol
  • hydrocarbon solvents such as methyl acetate and ethyl acetate or mixed solvents thereof, or more specifically water, lower alcohols, 1,3
  • the method for obtaining the extract is not particularly limited as long as it can obtain the onion, rice bran, bamboo, carrot, hibiscus, peppermint or aloe extract, specifically, the roots, stems of the peppermint or aloe,
  • the leaves, berries, flowers, their dried products, processed products and the like are immersed in the solvent, and cold extraction, heating extraction, ultrasonic extraction using ultrasonic wave extraction, reflux extraction using a reflux condenser, and the like can be used. .
  • fraction of the present invention means the result obtained by performing the fractionation to separate a specific component or a specific component group from a mixture comprising various various components.
  • Fractions in the present invention may be a fraction of the onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, pak extract or aloe extract.
  • the fractionation method of obtaining the fraction in the present invention is not particularly limited as long as it can exhibit an increase in skin elasticity and wrinkle improvement, but may be performed according to a method commonly used in the art.
  • solvent fractionation is performed by treating various solvents
  • ultrafiltration fractionation is performed by passing through an ultrafiltration membrane having a constant molecular weight cut-off value, and separation according to various chromatography (size, charge, hydrophobicity or affinity). Chromatographic fractionation, and combinations thereof).
  • the kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractionation solvents include polar solvents such as water, distilled water and alcohols; And nonpolar solvents such as hexane, ethyl acetate, chloroform, dichloromethane, and the like. These may be used alone or in combination of two or more thereof.
  • alcohol is used in the fractionation solvent, alcohols of C1 to C4 may be used.
  • the cosmetic composition of the present invention is a formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, glass Tofil, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol ), Sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, hoobac extract, aloe 0.0001 to 10% by weight (w / w) of at least one substance selected from the group consisting of the extract, the fraction of the pear extract and the fraction of the aloe extract, based on the total weight of the composition May include, may be
  • the cosmetic composition may promote differentiation of human adipose derived stem cells into adipocytes or proliferation of human adipose derived stem cells. That is, the cosmetic composition may be to promote the differentiation of human adipose derived stem cells into adipocytes, or to promote the proliferation of human adipose derived stem cells to increase skin elasticity and improve wrinkles.
  • human adipose derived stem cell refers to a multipotent cell capable of differentiating into various cells of the body as a stem cell that can be collected from human adipose tissue.
  • Adipose-derived stem cells are present in subcutaneous adipose tissue and have differentiation ability into adipocytes. Adipokine secreted by adipose-derived stem cells not only increases collagen synthesis in the dermal dermal layer, but also affects skin regeneration.
  • adipose cell refers to a cell that stores fat in adipose tissue of an individual, and may specifically mean white adipocytes present in the subcutaneous fat layer, but is not limited thereto. Do not.
  • human adipose derived stem cells form formononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacacaic acid, ubiquinone
  • the composition of the present invention comprising the above materials can be used for anti-aging purposes by increasing the elasticity of the skin and improving wrinkles.
  • human adipose derived stem cells raspberry ketone, gallic acid, caffeic acid, carnosic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione Treated with thioxane, lactoflavin, xanthophyll, onion, rice bran, bamboo, carrot, and hibiscus extract, significantly increased the cell activity rate of the cells of human adipose derived stem cells compared to the control group to promote its proliferation. Confirmed that it can. Therefore, the composition of the present invention comprising the above materials can be used for anti-aging purposes by increasing the elasticity of the skin and improving wrinkles.
  • the term "increased skin elasticity" of the present invention means to increase the elasticity of the skin by strengthening the subcutaneous fat layer structure of the individual by using the composition of the present invention.
  • the skin may be included without limitation, as long as the skin may have increased elasticity or wrinkles with the composition of the present invention.
  • improvement of the present invention is meant to alleviate the symptoms of skin wrinkles in an individual using the composition of the present invention.
  • One embodiment of the present invention is formononetin, (Emodin), Artepillin (Artepillin C), Carnosic acid (Palmitamide), Sodium Guazulene sulfonate (Sodium) Guaiazulene Sulfonate, Caffeic Acid, Acetyl Mandelic Acid, Laccaic Acid, Ubiquinone, Hydroxycinnamic Acid, Xanthophyll, Xanthophyll, Thick Extract, It provides a cosmetic composition for increasing the elasticity of the lips skin and improving wrinkles, comprising as an active ingredient one or more substances selected from the group consisting of aloe extracts, fractions of thick extracts and fractions of aloe extracts.
  • One embodiment of the present invention may be a cosmetic composition for increasing lip skin elasticity and improving wrinkles, which comprises at least one substance selected from the group consisting of a thick leaf extract and a fraction of a thick leaf extract.
  • the composition of the present invention is characterized by an excellent effect on such a skin of the lips.
  • the wrinkle improvement of the extract of the bakbak has an excellent effect on both the eyes and the lips, it was confirmed that the improvement rate and the improvement rate in the lips than the eyes.
  • the cosmetic composition for lip skin may be prepared in a formulation selected from the group consisting of lipstick, lip gloss, lip tint, and lip balm, but is not limited thereto.
  • the cosmetic composition is a solution, external ointment, cream, foam, nourishing longevity, softening longevity, pack, softening water, latex, makeup base, essence, soap, liquid detergent, bathing agent, sunscreen cream, sun oil, It may be prepared in a formulation selected from the group consisting of suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays, but It is not limited.
  • the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and as conventional components, for example, oil, water, surfactants, moisturizers, lower alcohols, Thickeners, chelating agents, pigments, preservatives, flavoring agents, and the like may be appropriately blended, but are not limited thereto.
  • one or more cosmetically acceptable carriers formulated in general skin cosmetics, and as conventional components, for example, oil, water, surfactants, moisturizers, lower alcohols, Thickeners, chelating agents, pigments, preservatives, flavoring agents, and the like may be appropriately blended, but are not limited thereto.
  • the cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the dosage form.
  • the carrier component is animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures of these may be used.
  • the formulation of the invention is a powder or a spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or mixtures thereof may be used, in particular in the case of a spray additionally chloro Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether.
  • solvents, solubilizers or emulsions are used as carrier components, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil may be used, in particular cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan may be used. have.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, micro Crystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the formulation of the present invention is a soap
  • alkali metal salts of fatty acids fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars and the like can be used as carrier components. have.
  • the cosmetic composition of the present invention is formononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrrhetinic acid, lanosterol , Sodium riboflavin phosphate, menadione, thioxtic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, thick pepper extract, aloe extract Auxiliaries commonly used in addition to one or more substances selected from the group consisting of fractions of the extracts such as hydrophilic or lipophilic gelling agents, hydrophilic Or a lipophilic active agents, preservatives, antioxidants
  • Another embodiment of the present invention is a formmononetine, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, Xanthophyll, Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, pepper extract, Aloe extract, a food composition for increasing skin elasticity and improving wrinkles comprising at least one substance selected from the group consisting of fractions of the extract as an active ingredient Ball.
  • the composition may promote the differentiation of human adipose
  • the present invention is a formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, Foodstuffs that include food acceptable salts of gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin or xanthophyll as active ingredients Provides food composition for increasing skin elasticity and improving wrinkles.
  • a "food acceptable salt” refers to formmononetin, emodine, artepilin, carnosic acid, palmiamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacacaic acid, ubiquinone , Hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin or xanthophyll
  • a combined salt it means a substance that can exhibit a similar activity to the compound in food.
  • the food composition of the present invention is a formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrrhetinic acid, lanosterol , Sodium riboflavin phosphate, menadione, thioxtic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, thick pepper extract, aloe extract
  • a food supplement acceptable food additive may include a food supplement acceptable food additive.
  • the "food supplement” means a component that can be added to food supplements, and can be appropriately selected and used by those skilled in the art to be added to prepare a health functional food of each formulation.
  • food additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners. , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like, but is not limited thereto.
  • Functional food composition of the present invention may include a health functional food.
  • the "health functional food” refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body.
  • the term “functionality” means obtaining useful effects on health purposes such as nutrient control or physiological effects on the structure and function of the human body.
  • the health functional food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding raw materials and ingredients commonly added in the art.
  • the formulation of the health functional food may also be prepared without limitation as long as the formulation is recognized as a health functional food.
  • Food composition of the present invention can be prepared in various forms of formulation, unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a raw material, and excellent portability, Health functional foods can be taken as supplements to increase skin elasticity and improve wrinkles.
  • the health functional food of the present invention can take, and may include all foods in a conventional meaning, and may be mixed with terms known in the art such as functional foods.
  • the health functional food of the present invention may be prepared by mixing known additives with other appropriate auxiliary ingredients that may be included in the food according to the choice of those skilled in the art. Examples of foods that can be added include meat, sausages, breads, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, various soups, beverages, teas, drinks, alcoholic beverages and Vitamin complexes; It also includes foods used as feed for animals.
  • Another embodiment of the present invention is a formmononetine, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, Xanthophyll, Raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, pepper extract, To prepare a pharmaceutical composition for increasing skin elasticity and improving wrinkles comprising aloe extract, at least one substance selected from the group consisting of fractions of the extract as an active ingredient Ball.
  • the composition may increase skin elasticity and improve wrinkles by promoting differentiation of human adipose derived stem cells into adipocytes.
  • the formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, hubac, aloe, Extracts, fractions, skin elasticity increase and improvement are as described above.
  • the present invention also relates to the formation of formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid or xanthophyll. It provides a pharmaceutical composition for increasing skin elasticity and improving wrinkles, including a pharmaceutically acceptable salt as an active ingredient.
  • a "pharmaceutically acceptable salt” refers to formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone , Hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin or xanthophyll
  • a combined salt it means a substance that can exhibit a similar activity to the pharmaceutical compound.
  • the pharmaceutical composition of the present invention may also be used as a single agent, and may be prepared and used as a complex preparation further including a drug known to have an effect of increasing skin elasticity and improving wrinkles, and may be formulated using a pharmaceutically acceptable carrier or excipient. It may be prepared in unit dose form or incorporated into a multi-dose container.
  • the pharmaceutical composition may be administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is determined by the type and severity of the individual, age, sex, activity of the drug, drug Sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
  • Another embodiment of the present invention is a formmononetine, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, Xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin, onion extract, rice bran extract, bamboo extract, It provides a quasi-drug composition for increasing skin elasticity and improving wrinkles comprising at least one substance selected from the group consisting of carrot extracts, hibiscus extracts, thick extracts, aloe extracts, fractions of the extracts as an active ingredient.
  • the composition may increase skin elasticity and improve wrinkles by promoting differentiation of human adipose derived stem cells into adipocytes.
  • the present invention is a formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, Pharmaceutically acceptable salts of gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin, or xanthophyll as active ingredients To provide a quasi-drug composition for increasing skin elasticity and improve wrinkles.
  • the "pharmaceutically acceptable salts" are as described above.
  • the quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent as necessary in addition to the above components.
  • a pharmaceutically acceptable carrier, excipients or diluents are not limited so long as they do not impair the effects of the present invention and include, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, and the like. It may include.
  • the "pharmaceutically acceptable carrier” may refer to a carrier, excipient or diluent that does not impair the biological activity and properties of the compound to be injected, without stimulating the organism, specifically, non-naturally occuring carrier).
  • the type of the carrier usable in the present invention is not particularly limited, and any carrier can be used as long as it is a conventionally used and pharmaceutically acceptable carrier in the art.
  • Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more thereof.
  • compositions comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used.
  • solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose, lactose, It can be prepared by mixing gelatin and the like.
  • lubricants such as magnesium stearate, talc can also be used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups.In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
  • Uittepsol, macrogol, Tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the quasi-drug composition of the present invention may be exemplified by disinfecting detergents, shower foams, ointments, wet tissues, coatings, etc., but is not limited thereto.
  • Formulation methods, dosages, methods of use, components, etc. of the quasi-drugs are well known in the art. It may be appropriately selected from the description of.
  • the quasi-drug composition of the present invention can be used in a method for improving skin wrinkles, comprising applying to the skin of an individual.
  • the subject includes, without limitation, mammals including rats, livestock, humans and the like.
  • Another embodiment of the present invention is a formmononetin, emodine, artepilin, carnosic acid, palmitamide, sodium guazulene sulfonate, caffeic acid, acetyl mandelic acid, lacaic acid, ubiquinone, hydroxycinnamic acid Xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioxane, lactoflavin, onion extract, rice bran extract, bamboo extract
  • a composition for promoting differentiation of human fat-derived stem cells comprising at least one substance selected from the group consisting of a carrot extract, a hibiscus extract, a thick pepper extract, an aloe extract, a fraction of a pepper extract and a fraction of an aloe extract as an active ingredient.
  • the composition may increase skin elasticity and improve wrinkles by promoting differentiation of human adipose derived stem cells into adipocytes.
  • Another aspect of the invention provides a method of increasing skin elasticity comprising administering the composition to a subject other than a human.
  • the term "administration" means introducing a composition of the present invention to a patient in any suitable manner, and the route of administration of the composition may be administered via any general route as long as it can reach the desired tissue.
  • Intraperitoneal administration intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, but is not limited thereto. Due to the characteristics of the composition of the present invention having an effect on improving skin elasticity and improving wrinkles, the route of administration of the composition may be applied to the skin.
  • composition of the present invention may be administered daily or intermittently, and the number of administrations per day may be administered once or divided into two or three times.
  • composition of the present invention can be used alone or in combination with other drug treatments to enhance skin elasticity and improve wrinkles. In consideration of all the above factors, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.
  • the term "individual” refers to all animals including rats, mice, domestic animals, and the like, including humans, which have reduced skin elasticity, wrinkled skin, or may occur. Specifically, it may be a mammal including a human.
  • the thick gourd extract of the present Example was purchased from Borak Co., Ltd. (Hwaseong, Gyeonggi-do, Korea), and the powder of Magnoliae Cortex was dissolved in a solvent such as DPG and DMSO, and then filtered through a 0.2 ⁇ m syringe filter to use the filtered liquid as a thick gourd extract. It was.
  • Aloe Vera (Aloe Vera) was purchased from the domestic farm, and extracted once with 70% methanol at 1:10 ratio.
  • Example 2 Confirmation of the effect of promoting the differentiation of human fat-derived stem cells of formononetin, acetyl mandelic acid, and hubac extract
  • Human adipose derived stem cells were purchased from Lonza Inc (Lonza Inc, Walkersvile, MD, USA) and cultured according to Lonza's experimental guidelines. Differentiation into adipocytes was tested using differentiation medium recommended by Lonza. As a positive control, rosiglitazone 1uM was used as the differentiation medium. To induce differentiation of adipocyte-derived stem cells into adipocytes, 3 to 5 days after the incubation of the cells, the cell culture medium was removed and treated with formononetin, acetyl mandelic acid and thick extract and positive control for 14 days.
  • Example 3 Quantitative Confirmation of the Differentiation Promoting Effects of 12 Compounds Including Formononetine, Thick Extracts and Aloe Extracts on Human Adipose Stem Cells
  • Example 2 In the same manner as in Example 2, after treating 12 kinds of compounds including formonenetine, hubac extract and aloe extract to cultured human adipose derived stem cells, eluting the oil red o stained with 100% isopropanol solution, 490nm Absorbance was measured and quantified at the wavelength, and the result is shown in FIG. 2. From this, 14 kinds of substances including the formonenetine of the present invention showed a significant increase in relative differentiation rate compared to the negative control treated with differentiation medium, respectively, promoting the differentiation of adipocyte-derived stem cells into adipocytes, and kaperpherol (kaempherol). Compared with non-differentiated material such as), it was confirmed that it can effectively promote differentiation into adipocytes. Therefore, the composition of the present invention comprising the above substance can be used for anti-aging purposes to promote differentiation of adipose derived stem cells and increase subcutaneous adipocytes, thereby increasing skin elasticity and improving wrinkles.
  • the huhu extract extract was treated to wrinkles of the skin of the lips and the skin of the subjects (total number of subjects: 12).
  • the wrinkles of the skin of the lips were measured by designating the most protruding portion of the lower lip by a certain length through Janus photographing, and obtaining the standard deviation of the contrast values.
  • the standard deviation range of the contrast value was 3 to 12, and the more the deep wrinkles, the larger the standard deviation was confirmed.
  • the wrinkles of the skin under the eye were measured by calculating the area of wrinkles in the Janus wrinkle analysis program, that is, through Janus photography. The value of the wrinkles was confirmed to represent a range of 7 to 44.
  • the change in the lip wrinkle value of 1 or more and the change in the fold wrinkle value of 4 or more were classified as improved results.
  • the classification criterion was confirmed that the numerical value that can clearly distinguish the improvement with the naked eye is 2 lip wrinkles, 8 wrinkles under the eyes, because 1/2 of this value was selected as a criterion for improvement.
  • the extract of bakbak has an effect of improving the wrinkles of the skin, in particular, it is more effective in improving the wrinkles of the skin of the lips.
  • the extracts of the onion, rice bran, bamboo, carrot, and hibiscus were each extracted using methanol, and then dried and used in powder form.
  • Human adipose derived stem cells were purchased from Lonza, Inc. Walkersville, MD, USA and then cultured in a carbon dioxide incubator at 37 degrees Celsius, 5% carbon dioxide conditions. Each material was treated at a concentration of 0.2ppm, 2ppm, and 20ppm, and then the degree of cellular activity of human adipose stem cells was confirmed using CCK-8 kit (Dojindo). As a result, each material showed the highest activity at the concentration of Table 1 below, all showed a cell activity higher than 20% higher than the untreated group (control) (Fig. 6).
  • a total of 19 compounds or extracts of the present invention significantly promote the proliferation of human adipose derived stem cells, and can be used for anti-aging by increasing skin elasticity and improving wrinkles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne : une composition cosmétique, une composition alimentaire, une composition pharmaceutique, une composition de quasi-médicament, destinées à renforcer l'élasticité de la peau et à réduire les rides, ou une composition visant à favoriser la différenciation ou la prolifération de cellules souches dérivées du tissu adipeux humain, qui contiennent toutes, en tant que principe(s) actif(s), une ou plusieurs substances choisies dans le groupe constitué par la formononétine, l'émodine, l'artépilline C, l'acide carnosique, le palmitamide, le sulfonate de guaiazulène sodique, l'acide cafféique, l'acide acétylmandélique, l'acide laccaïque, l'ubiquinone, l'acide hydroxycinnamique, le xanthophylle, la cétone de framboise, l'acide gallique, le terpinéol, le phosphate de mannose sodique, la tropolone, l'acide glycyrrhétinique, le lanostérol, le phosphate de riboflavine sodique, la ménadione, l'acide thioctique, la lactoflavine, un extrait d'oignon, un extrait de son de riz, un extrait de bambou, un extrait de carotte, un extrait d'hibiscus, un extrait de Magnolia officinalis, un extrait d'aloès et des fractions de ces extraits ; et un procédé visant à renforcer l'élasticité de la peau, comprenant une étape d'administration de la composition à un sujet à l'exclusion des êtres humains.
PCT/KR2019/010815 2018-08-23 2019-08-23 Composition visant à favoriser la différenciation ou la prolifération de cellules souches adipeuses humaines WO2020040621A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2021534101A JP2021535208A (ja) 2018-08-23 2019-08-23 ヒト脂肪幹細胞の分化または増殖促進用組成物
CN201980055771.1A CN112638357B (zh) 2018-08-23 2019-08-23 用于促进源自人脂肪的干细胞的分化或增殖的组合物
US17/270,697 US20210315799A1 (en) 2018-08-23 2019-08-23 Composition for Promoting Differentiation or Proliferation of Human Adipose-Derived Stem Cell
CN202410183350.XA CN118021632A (zh) 2018-08-23 2019-08-23 用于促进人脂肪干细胞的分化或增殖的组合物
JP2023174389A JP2024009897A (ja) 2018-08-23 2023-10-06 ヒト脂肪幹細胞の分化または増殖促進用組成物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20180098717 2018-08-23
KR10-2018-0098717 2018-08-23
KR10-2018-0109108 2018-09-12
KR1020180109108A KR102311011B1 (ko) 2018-09-12 2018-09-12 인간지방줄기세포의 증식 촉진용 조성물
KR10-2019-0029998 2019-03-15
KR1020190029998A KR102199678B1 (ko) 2018-08-23 2019-03-15 인간지방줄기세포의 분화 촉진용 조성물

Publications (1)

Publication Number Publication Date
WO2020040621A1 true WO2020040621A1 (fr) 2020-02-27

Family

ID=69593327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/010815 WO2020040621A1 (fr) 2018-08-23 2019-08-23 Composition visant à favoriser la différenciation ou la prolifération de cellules souches adipeuses humaines

Country Status (3)

Country Link
JP (2) JP2021535208A (fr)
CN (1) CN118021632A (fr)
WO (1) WO2020040621A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022169246A1 (fr) * 2021-02-02 2022-08-11 주식회사 엘지생활건강 Composition de matière cosmétique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
JP2008024600A (ja) * 2006-07-18 2008-02-07 Naris Cosmetics Co Ltd アクロレイン付加体形成阻害剤、及びそれを含有する皮膚抗老化外用剤および抗老化飲食品
KR100844516B1 (ko) * 2007-02-12 2008-07-08 주식회사 사임당화장품 황기 추출물을 함유하는 화장료 조성물
KR20130037563A (ko) * 2011-10-06 2013-04-16 (주)아모레퍼시픽 한후박 추출물을 유효성분으로 함유하는 레티노익산 수용체의 활성화를 통한 항노화용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
JP2008024600A (ja) * 2006-07-18 2008-02-07 Naris Cosmetics Co Ltd アクロレイン付加体形成阻害剤、及びそれを含有する皮膚抗老化外用剤および抗老化飲食品
KR100844516B1 (ko) * 2007-02-12 2008-07-08 주식회사 사임당화장품 황기 추출물을 함유하는 화장료 조성물
KR20130037563A (ko) * 2011-10-06 2013-04-16 (주)아모레퍼시픽 한후박 추출물을 유효성분으로 함유하는 레티노익산 수용체의 활성화를 통한 항노화용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE, H.: "Effects of Bambusa tulda on the proliferation of human stem cells", EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 14, no. 6, 1 December 2017 (2017-12-01), pages 5696 - 5702, XP055688221, ISSN: 1792-0981, DOI: 10.3892/etm.2017.5276 *
SEONJU LEE ET AL: "Effects of Magnolia Officinalis Bark Extract on Improvement of Lip Wrinkles", J. SOC. COSMET. SCI. KOREA, vol. 45, no. 1, 1 March 2019 (2019-03-01), pages 95 - 103, XP055688229, ISSN: 1226-2587, DOI: 10.15230/SCSK.2019.45.1.95 *
WIDOWATI, W.: "Effect of 13-carotene on cell proliferation and differentiation of adipose-derived stem cells into endothelial progenitor cells", BIOTECHNOLOGY: AN INDIAN JOURNAL, vol. 9, no. 10, 1 January 2014 (2014-01-01), pages 407 - 412, XP055603622 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022169246A1 (fr) * 2021-02-02 2022-08-11 주식회사 엘지생활건강 Composition de matière cosmétique

Also Published As

Publication number Publication date
JP2021535208A (ja) 2021-12-16
JP2024009897A (ja) 2024-01-23
CN118021632A (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
WO2021221405A1 (fr) Composition cosmétique fonctionnelle comprenant un extrait végétal comme principe actif et son procédé de préparation
WO2021137677A1 (fr) Composition contenant un extrait de plante
WO2020218781A1 (fr) Composition fonctionnelle contenant un milieu de culture riche en exosomes dérivé d'une cellule souche immortalisée et un extrait de bourgeon de rose en tant que principes actifs
WO2015056982A1 (fr) Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées au moyen dudit procédé
WO2012002784A2 (fr) Composition contenant des extraits de mûrier à papier
WO2020122360A1 (fr) Procédé de préparation d'un extrait de zizania latifolia turcz. traité avec une enzyme présentant une teneur accrue en tricine, et composition de blanchissement, réduction des rides, anti-inflammatoire, antiallergique et d'hydratation, préparée avec ce dernier
WO2010123184A1 (fr) Composition pour prévenir et traiter l'alopécie, à base de composés de norgalanthamine
KR101908077B1 (ko) 천연 한방 추출물을 유효성분으로 포함하는 미백, 피부 노화 방지 또는 피부 주름 개선용 조성물
WO2018004141A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'exfolier la peau, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant, en tant qu'ingrédient actif, un ou plusieurs composés choisis dans le groupe constitué du cimène, de l'acide béhénique, du 2-méthoxynaphtalène, du thymol et de leurs sels
WO2013129723A1 (fr) Composition d'amélioration d'états de la peau comprenant de l'hordénine
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2020040621A1 (fr) Composition visant à favoriser la différenciation ou la prolifération de cellules souches adipeuses humaines
WO2018062820A1 (fr) Composition visant à prévenir la chute des cheveux et à en favoriser la pousse, comprenant un phytoœstrogène en tant que principe actif
WO2012173382A2 (fr) Composition à usage externe pour l'épiderme, contenant du tanshinone ii a en tant que principe actif
WO2020032296A1 (fr) Composition fonctionnelle
WO2019168348A1 (fr) Composition de prévention de la chute des cheveux et de stimulation de la pousse des cheveux
WO2015037855A1 (fr) Composition comprenant un extrait d'herbes combinées comprenant de l'acanthopanax koreanum naka et du crinum asiaticum var. japonicum présentant une activité de prévention de la calvitie et une activité de stimulation de la croissance capillaire
WO2009151212A2 (fr) Composition de préparation externe cutanée contenant des extraits de fleurs et de graines de ginseng
WO2012173383A2 (fr) Composition à usage externe pour l'épiderme, contenant en tant que principe actif du cryptotanshinone
KR102184156B1 (ko) 인간지방줄기세포의 분화 촉진용 조성물
WO2013024960A1 (fr) Composition médicale contenant un extrait de stauntonia hexaphylla
WO2016122091A1 (fr) Composition pharmaceutique pour la prévention et le traitement de maladie allergique ou de dermatite de contact, comprenant un extrait de cymbidium comme principe actif
CN112638357A (zh) 用于促进人脂肪干细胞的分化或增殖的组合物
WO2020218840A1 (fr) Composition pour inhiber la perte des cheveux ou favoriser la pousse des cheveux contenant un extrait de plante débarrassé de chlorophylle ou de pigment en tant que principe actif, et son procédé de production
WO2014014177A1 (fr) Composition, comprenant un extrait de dendropanax morbifera ou un composé dérivé de celui-ci comme principe actif, destinée à la prévention et au traitement de l'hyperplasie prostatique bénigne

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19853214

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021534101

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08.07.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19853214

Country of ref document: EP

Kind code of ref document: A1